Study guide
3.3 ICRU Target Volume Definitions (GTV, CTV, PTV, PRV, OAR)
ARRT Radiation Therapy Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Patient Care & Education
1.1 Patient Assessment, History, and Vital Signs 1.2 Psychosocial Support & Coping Mechanisms 1.3 Patient & Family Education on Radiation Therapy 1.4 Radiation Side Effect Management: Skin & Mucosal Reactions 1.5 Radiation Side Effect Management: Systemic & Organ-Specific Side Effects 1.6 Nutritional Support & Management of Dysphagia/Odynophagia 1.7 Medical Emergencies in Radiation Oncology 1.8 Patient Rights, Informed Consent, and Advanced Directives 1.9 Ethical, Legal, and HIPAA Considerations for Radiation Therapists 1.10 Infection Control & Sterile Technique in Radiation Therapy 1.11 Transfer & Positioning Safety for Oncology Patients 1.12 Pharmacology & Contrast Media in Radiation Therapy 1.13 Cancer Epidemiology, Screening & Diagnostic Evaluation
2 Chapter 2: Radiation Physics, Radiobiology & Protection
2.1 Structure of Matter, Electromagnetic & Particulate Radiation 2.2 Radiation Production in Linear Accelerators & X-Ray Tubes 2.3 Photon & Electron Beam Interactions with Matter 2.4 Radiation Measurement Quantities, Units & Dosimeters 2.5 Radiation Protection Principles: ALARA, Time, Distance & Shielding 2.6 NCRP Dose Limits for Occupational & Public Exposure 2.7 Vault Design, Primary & Secondary Protective Barriers 2.8 Radiobiology Principles: Cell Survival Curves & Radiosensitivity (4 R's) 2.9 Linear Energy Transfer (LET) & Relative Biological Effectiveness (RBE) 2.10 Acute & Late Radiation Effects on Normal Tissues 2.11 Radiation Safety Rules, Emergency Procedures & Sealed Source Safety 2.12 MRI Magnetic Field Screening for Radiation Therapy Patients
3 Chapter 5: Treatment Sites, Tumors & Classification
5.1 Brain, Spinal Cord Tumors & Metastatic Patterns 5.2 Head & Neck Sites: Anatomy, Lymphatics & Patterns of Spread 5.3 Breast Cancer: Anatomy, Lymphatic Drainage & Radiation Considerations 5.4 Lung & Thoracic Tumors: Anatomy, Spread & Critical Structures 5.5 Abdomen, Pelvis, GI & GU Sites: Anatomy & Metastatic Patterns 5.6 Reproductive System Tumors: Prostate, Cervix & Related Sites 5.7 Lymphoma, Sarcoma, Skin, Leukemia & Oncologic Emergencies 5.8 Tumor Classification: Histopathology, Grade & Staging Systems
4 Chapter 3: Treatment Planning & Dosimetry
3.1 CT Simulation, Patient Positioning & Target Localization 3.2 Immobilization Devices & Radiopaque Marking Protocols 3.3 ICRU Target Volume Definitions (GTV, CTV, PTV, PRV, OAR) 3.4 Beam Modifiers: Wedges, Compensators, Bolus & MLC Systems 3.5 Depth Dose Characteristics: PDD, TMR, TPR & TAR Relationships 3.6 Monitor Unit (MU) Calculations & Clinical Dosimetry Formulas 3.7 3D Conformal Radiation Therapy (3D-CRT) Beam Arrangements 3.8 IMRT, VMAT & Inverse Planning Optimization Concepts 3.9 SRS, SBRT & Stereotactic Radiosurgery Techniques 3.10 Brachytherapy Principles, HDR, LDR & Isotopes 3.11 Dose Volume Histograms (DVH) & QUANTEC Tissue Tolerances
5 Chapter 4: Treatment Delivery, Image Guidance & QA
4.1 Pre-Treatment Chart Check & Plan Verification Protocols 4.2 Daily Patient Positioning, Setup Tolerances & Alignment Verification 4.3 Image-Guided Radiation Therapy (IGRT): Portal Imaging & CBCT Verification 4.4 Linear Accelerator Safety Systems, Interlocks & Gantry Controls 4.5 Special Techniques: TBI, TSI, SGRT & Gated Radiotherapy 4.6 Daily Linac Quality Assurance per AAPM TG-142 Specifications 4.7 Monthly & Annual Linac QA Requirements & Dosimetric Calibration 4.8 Patient-Specific IMRT QA & In-Vivo Dosimetry Verification 4.9 Machine Malfunctions, Override Protocols & Emergency Off Procedures 4.10 Record and Verify (R&V) Systems, EHR Integration & Treatment Documentation
3.3 ICRU Target Volume Definitions (GTV, CTV, PTV, PRV, OAR)
Key Takeaways Explain This Topic AI
Gross Tumor Volume (GTV) represents the demonstrable, palpable, or radiologically visible extent and location of malignant growth.
Clinical Target Volume (CTV) expands the GTV to encompass subclinical microscopic disease spread that cannot be visually imaged.
Internal Target Volume (ITV) accounts for internal physiological organ motion (e.g., respiration, bladder filling) by adding an internal margin (IM) to the CTV.
Planning Target Volume (PTV) adds a setup margin (SM) to the CTV or ITV to compensate for mechanical and positioning uncertainties.
Planning Organ at Risk Volume (PRV) adds a safety margin around critical Organs at Risk (OAR) to prevent accidental overdose from setup variations.
Last updated: July 2026
Standardized Target Volumes: ICRU Reports 50, 62, and 83
To standardize prescription patterns, treatment reporting, and inter-institutional clinical trials, the International Commission on Radiation Units and Measurements established explicit definitions for target and normal tissue volumes in ICRU Report 50 (1993) , ICRU Report 62 (1999) , and ICRU Report 83 (2010) for IMRT.
Radiation oncology plans do not simply target the visible tumor; they construct nested geometric expansions designed to capture microscopic disease, physiological motion, and daily positioning errors. +-------------------------------------------------------------+
- | Planning Target Volume (PTV) |
- | +-----------------------------------------------------+ |
- | | Internal Target Volume (ITV) | |
- | | +---------------------------------------------+ | |
- | | | Clinical Target Volume (CTV) | | |
- | | | +-------------------------------------+ | | |
- | | | | Gross Tumor Volume (GTV) | | | |
- | | | | (Visible / Palpable Disease) | | | |
- | | | +-------------------------------------+ | | |
- | | +---------------------------------------------+ | |
- | +-----------------------------------------------------+ |
- +-------------------------------------------------------------+
- Detailed ICRU Target Definitions
- 1. Gross Tumor Volume (GTV)
The Gross Tumor Volume (GTV) is the demonstrable extent and location of the malignant growth. It consists of primary disease, metastatic regional lymph nodes, or distant metastases identifiable via physical examination or imaging modalities (CT, MRI, PET, ultrasound).
Note: In post-operative patients who have undergone complete surgical resection, GTV = 0 (no visible tumor remains).
2. Clinical Target Volume (CTV)
The Clinical Target Volume (CTV) is a tissue volume containing the GTV plus an anatomical expansion to encompass subclinical microscopic malignant disease . Microscopic spread cannot be imaged directly but is known to exist based on pathological patterns.
Expansion Example: For a high-grade glioma, the CTV equals GTV + 1.5 cm to 2.0 cm margin for infiltrating tumor cells. For prostate adenocarcinoma, CTV includes the prostate gland plus the proximal seminal vesicles and pelvic lymph node chains.
3. Internal Target Volume (ITV)
Introduced in ICRU Report 62 , the Internal Target Volume (ITV) consists of the CTV plus an Internal Margin (IM) . The internal margin compensates for expected physiological variations in target size, shape, and position within the patient during treatment (e.g., respiration, bowel peristalsis, rectal gas, bladder filling). ITV = CTV + Internal Margin (IM) \text{ITV} = \text{CTV} + \text{Internal Margin (IM)} ITV = CTV + Internal Margin (IM)
4. Planning Target Volume (PTV)
The Planning Target Volume (PTV) is a geometric concept designed to ensure that the prescribed radiation dose is delivered to the CTV/ITV despite physical variations. The PTV adds a Setup Margin (SM) to account for external positioning uncertainties, patient translation, linac calibration drift, and mechanical laser tolerances. PTV = ITV + Setup Margin (SM) = CTV + IM + SM \text{PTV} = \text{ITV} + \text{Setup Margin (SM)} = \text{CTV} + \text{IM} + \text{SM} PTV = ITV + Setup Margin (SM) = CTV + IM + SM
Van Herk's margin formula is frequently used in clinical physics to compute optimal PTV margins based on systematic ( Σ \Sigma Σ ) and random ( σ \sigma σ ) setup uncertainties: PTV Margin = 2.5 Σ + 0.7 σ \text{PTV Margin} = 2.5\Sigma + 0.7\sigma PTV Margin = 2.5Σ + 0.7 σ
- ICRU Volume Definition Clinical Basis Example (Lung Cancer)
- GTV Visible gross tumor mass PET/CT imaging density 3.5 cm spiculed lung lesion
- CTV GTV + microscopic disease margin Histopathological invasion GTV + 6 mm anatomical expansion
ITV CTV + internal physiological motion 4D-CT respiratory phase envelope Motion envelope encompassing 1.5 cm excursion
- PTV ITV + setup uncertainty margin Machine lasers, daily setup errors ITV + 5 mm isotropic setup expansion
- PRV OAR + safety margin Prevents accidental OAR overdose Spinal cord + 3 mm safety expansion
- Normal Tissue Volumes: OAR, PRV, Treated, and Irradiated Volumes
- Organ at Risk (OAR)
An Organ at Risk (OAR) is a normal tissue organ whose radiation sensitivity may significantly influence treatment planning or dose prescription. OARs are classified by radiobiological architecture:
Serial Organs: Function is lost if a single subunit is disabled (e.g., spinal cord, brainstem, optic nerve). Max dose ( D max D_{\max} D m a x ) is critical.
Parallel Organs: Function is maintained if a critical volume fraction remains undamaged (e.g., lung, liver, parotid glands). Mean dose ( D mean D_{\text{mean}} D mean ) or volume constraints ( V 20 V_{20} V 20 ) are critical.
Planning Organ at Risk Volume (PRV)
Analogous to the PTV for target volumes, a Planning Organ at Risk Volume (PRV) adds a safety margin around an OAR to account for setup variability and internal organ movement. For example, a 3 mm PRV expansion around the spinal cord ensures that positioning shifts do not push the high-dose PTV gradient into the actual spinal cord tissue.
Treated Volume and Irradiated Volume
Treated Volume: The volume of tissue enclosed by an isodose surface (e.g., 95% isodose line) selected as appropriate to achieve the therapeutic purpose.
Irradiated Volume: The volume of tissue receiving a dose that is significant in relation to normal tissue tolerance (typically the 50% isodose volume).
ICRU 83 Dose Prescription and Reporting Metrics
In modern 3D-CRT and IMRT planning, ICRU 83 mandates reporting specific dose-volume parameters from the Cumulative Dose-Volume Histogram (DVH):
D 50 % D_{50\%} D 50% (Median Dose): Dose received by 50% of the target volume. Represents the mean prescription dose.
D 98 % D_{98\%} D 98% (Near-Minimum Dose): Dose received by 98% of the PTV. Defines target coverage adequacy.
D 2 % D_{2\%} D 2% (Near-Maximum Dose): Dose received by 2% of the PTV. Defines hot spots within the target volume.
Conformity Index (CI): Measures how closely the prescription isodose volume matches the PTV contour.